Sakr Hany, Cook James R
Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):410-415. doi: 10.1097/PAI.0000000000000657.
Aggressive lymphomas with MYC and BCL2 and/or BCL6 translocations ("double hit" lymphomas, DHL) represent a distinct diagnostic category in the updated World Health Organization (WHO) classification. The diagnostic yield of MYC immunohistochemistry (IHC) for the identification of DHL is currently uncertain. MYC IHC was performed in 272 consecutive cases of aggressive B-cell lymphoma, and results correlated with fluorescence in situ hybridization (FISH) for MYC translocations. Among 156 patients with IHC and FISH data, MYC IHC identified MYC translocations with 89% sensitivity, 38% specificity, 92% negative predictive value, and 29% positive predictive value. Three of 15 (20%) of DHL were MYC IHC negative. One case contained a MYC translocation detectable IGH/MYC fusion probes but not MYC break-apart probes. A subset of DHL lack MYC protein expression, and recognition of this subset of cases requires FISH testing. These results provide an appropriate diagnostic algorithm for implementation of 2016 WHO diagnostic criteria.
伴有MYC和BCL2及/或BCL6易位的侵袭性淋巴瘤(“双打击”淋巴瘤,DHL)在更新后的世界卫生组织(WHO)分类中代表一种独特的诊断类别。目前,MYC免疫组化(IHC)对DHL的诊断价值尚不确定。对272例连续性侵袭性B细胞淋巴瘤病例进行了MYC IHC检测,并将结果与MYC易位的荧光原位杂交(FISH)结果进行了对比。在156例有IHC和FISH数据的患者中,MYC IHC检测MYC易位的灵敏度为89%,特异度为38%,阴性预测值为92%,阳性预测值为29%。15例DHL中有3例(20%)MYC IHC结果为阴性。1例病例含有可通过IGH/MYC融合探针检测到的MYC易位,但MYC断裂分离探针检测结果为阴性。一部分DHL缺乏MYC蛋白表达,识别这类病例需要进行FISH检测。这些结果为实施2016年WHO诊断标准提供了合适的诊断算法。